RxDoctor Payments Data

James Bush, MD

Internal Medicine · Hopewell, VANPI 1942273909

Payments from drug & device makers

$356in general payments, 2019–2025

Across 21 payments — averaging $16.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$187
  • Supernus Pharmaceuticals, Inc.$71
  • AbbVie$47
  • Pfizer$24
  • Takeda Pharmaceuticals U.S.A., Inc.$14
  • Amgen$13

What the payments were for

  • Food & beverage$32892%
  • Education$288%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$356 in reported general payments places this provider in the 60th percentile of 2,724 internal medicine providers in Virginia.

See all internal medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$255,537
Medicare patients
519
Services billed
3,590

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban88$81,771
TrulicityDulaglutide54$63,864
JardianceEmpagliflozin44$49,954
OzempicSemaglutide48$43,242
JanuviaSitagliptin Phosphate30$29,864
JanumetSitagliptin Phos/Metformin Hcl17$21,723
XareltoRivaroxaban21$18,627
EntrestoSacubitril/Valsartan21$16,114
Soliqua 100-33Insulin Glargine/Lixisenatide17$15,487
TradjentaLinagliptin18$13,542
Breztri AerosphereBudesonide/Glycopyr/Formoterol11$11,947
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog24$11,489
Lantus SolostarInsulin Glargine,hum.Rec.Anlog58$7,733
NamzaricMemantine Hcl/Donepezil Hcl11$6,964
Repatha SureclickEvolocumab13$6,906

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Premarin$24$84,329101 claims
AstraZenecaBreztri Aerosphere$187$11,94711 claims
AbbVieNamzaric$47$6,96411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 2,724 internal medicine providers in Virginia.

Other internal medicine in Hopewell

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →